NOVN.CH

120.74

-1.08%↓

LONN.CH

517.4

+0.43%↑

SDZ.CH

66

-1.17%↓

STMN.CH

84.54

-0.14%↓

BANB.CH

69.9

+5.35%↑

NOVN.CH

120.74

-1.08%↓

LONN.CH

517.4

+0.43%↑

SDZ.CH

66

-1.17%↓

STMN.CH

84.54

-0.14%↓

BANB.CH

69.9

+5.35%↑

NOVN.CH

120.74

-1.08%↓

LONN.CH

517.4

+0.43%↑

SDZ.CH

66

-1.17%↓

STMN.CH

84.54

-0.14%↓

BANB.CH

69.9

+5.35%↑

NOVN.CH

120.74

-1.08%↓

LONN.CH

517.4

+0.43%↑

SDZ.CH

66

-1.17%↓

STMN.CH

84.54

-0.14%↓

BANB.CH

69.9

+5.35%↑

NOVN.CH

120.74

-1.08%↓

LONN.CH

517.4

+0.43%↑

SDZ.CH

66

-1.17%↓

STMN.CH

84.54

-0.14%↓

BANB.CH

69.9

+5.35%↑

Search

Roche Holding AG

Closed

SectorHealthcare

327 -0.43

Overview

Share price change

24h

Current

Min

323

Max

328.6

Key metrics

By Trading Economics

Income

1.8B

5.5B

Sales

15B

31B

P/E

Sector Avg

20.586

66.418

Dividend yield

2.95

Profit margin

17.892

Employees

103,249

EBITDA

5.1B

12B

Dividends

By Dow Jones

Dividend yield

Sector Avg

2.95%

2.36%

Market Stats

By TradingEconomics

Market Cap

-26B

263B

Previous open

327.43

Previous close

327

News Sentiment

By Acuity

8%

92%

4 / 348 Healthcare

Roche Holding AG Chart

Past performance is not a reliable indicator of future results.

Related News

9 Mar 2026, 16:43 UTC

Major Market Movers

Roche Shares Fall After Breast-Cancer Treatment Misses Goal in Late-Stage Study -- Update

9 Mar 2026, 15:44 UTC

Major Market Movers

Correction to Roche Shares Article

9 Mar 2026, 09:51 UTC

Major Market Movers

Roche Shares Fall After Breast-Cancer Treatment Misses Goal in Late-Stage Study

6 Mar 2026, 09:24 UTC

Major Market Movers

Zealand Pharma Shares Plunge After Obesity Drug Candidate Disappoints in Trial

29 Jan 2026, 10:07 UTC

Earnings

Roche Forecasts 2026 Growth, Cites Drug-Pipeline Strength -- Update

29 Jan 2026, 07:07 UTC

Earnings

Roche Forecasts 2026 Growth, Helped by Strength of Drug Pipeline

10 Apr 2026, 11:28 UTC

Market Talk

Roche's Longer-Term Outlook to Take Spotlight at Diagnostics Event -- Market Talk

10 Apr 2026, 11:17 UTC

Market Talk

Roche to Face Significant Currency Headwinds -- Market Talk

11 Mar 2026, 10:57 UTC

Market Talk

Roche Sees Mixed Fortunes in Immunology, Oncology -- Market Talk

9 Mar 2026, 09:43 UTC

Hot Stocks

Stocks to Watch Monday: Lamb Weston, Carnival, Pfizer -- WSJ

6 Mar 2026, 07:22 UTC

Market Talk

Roche, Zealand Pharma Obesity Drug Falls Short of Expectations -- Market Talk

3 Mar 2026, 07:22 UTC

Market Talk

Roche's Multiple Sclerosis Drug Safety Remains in Focus After Latest Trial -- Market Talk

2 Mar 2026, 14:21 UTC

Market Talk

Roche's Multiple Sclerosis Drug Might Not Clear FDA Bar -- Market Talk

29 Jan 2026, 11:40 UTC

Market Talk
Earnings

Roche's Guidance Seems Less Conservative Than Expected -- Market Talk

29 Jan 2026, 06:05 UTC

Earnings

Roche Expects 2026 Core EPS to Increase in High-Single Digit Range at CER

29 Jan 2026, 06:04 UTC

Earnings

Roche Expects 2026 Mid-Single-Digit Range Sales Increase at Constant Currency

29 Jan 2026, 06:03 UTC

Earnings

Roche Issues 2026 View

29 Jan 2026, 06:02 UTC

Earnings

Analysts Saw 2025 Core EPS at CHF19.70

29 Jan 2026, 06:02 UTC

Earnings

Roche: 2025 Core EPS CHF19.46

29 Jan 2026, 06:01 UTC

Earnings

Analysts Had Seen 2025 Sales At CHF61.47B

29 Jan 2026, 06:01 UTC

Earnings

Roche 2025 Sales CHF61.52B

28 Jan 2026, 11:22 UTC

Earnings

Roche's Prospects in Weight-Loss Field to be in Focus -- Earnings Preview

27 Jan 2026, 11:31 UTC

Market Talk

Roche's Weight-Loss Study Results Seem Promising -- Market Talk

27 Jan 2026, 11:24 UTC

Market Talk

Roche Might Struggle to Leave Mark in Crowded Obesity Market With CT-388 -- Market Talk

27 Jan 2026, 09:30 UTC

Market Talk

Roche's CT-388 Could Compete With Lilly's Zepbound on Obesity Efficacy -- Market Talk

27 Jan 2026, 07:52 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Roche Obesity Study Data Look Encouraging -- Market Talk

16 Jan 2026, 17:03 UTC

Market Talk

All Eyes on Guidance for European Big Pharma Earnings Season -- Market Talk

12 Jan 2026, 14:50 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Pharma Sector Can Spend Big on M&A -- Market Talk

22 Dec 2025, 08:48 UTC

Market Talk

U.S. Administration's Deals With Big Pharma Unveil Pricing Uncertainty -- Market Talk

19 Nov 2025, 12:47 UTC

Market Talk

Roche's Breast Cancer Drug Trial Results Surprise Positively -- Market Talk

Peer Comparison

Price change

Roche Holding AG Forecast

Rating Consensus

By TipRanks

0 ratings

0

Buy

0

Hold

0

Sell

Sentiment

By Acuity

4 / 348 Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at transcription factor targets in oncology. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.
help-icon Live chat